BioSpace News Archive

According to Vision Research Reports, the U.S. virtual care market was estimated at USD 4.3 billion in 2021 and it is expected to surpass around USD 46.5 billion by 2030, poised to grow at a CAGR of 30.28% from 2022 to 2030.

Minimally invasive image-guided therapy start-up, SpinaFX Medical Inc., announced significant milestones hit since closing its $6.88M CDN Series A round in November 2021.

According to QY Research Medical, the Pharmaceutical Glycerin Based Products Market size was reached at $34.6 billion in 2020 and is projected to hit $61.6 billion by 2030, growing at a CAGR of 6 % from 2021 to 2030.

Repligen Corporation announced the appointment to its Board of Directors of Konstantin Konstantinov, Ph.D., a life sciences and bioprocessing industry expert.

Mereo BioPharma Group plc announced that on May 23, 2022, it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market, LLC notifying the Company that its American Depositary Shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of Nasdaq.

AB Science SA announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis, meaning that the information and materials submitted by AB Science has been screened and found acceptable for review as a New Drug Submission.

Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, announced the publication of updated results from the clinical trial of the lead asset from its ADXS-HOT off-the-shelf, cancer-type specific, immunotherapy program.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), today announced the online publication of the abstract for its lead program, PC14586, accepted as an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) annual meeting being held June 3-7, 2022 in Chicago, Illinois.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines, today announced an upcoming poster presentation of preliminary data from its ongoing Phase 2 VERSATILE-002 clinical trial at the American Society of Clinical Oncology (ASCO) Annual Meeting.

NKGen Biotech Inc., a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, today announced that clinical data from its ongoing SNK01 (NK cell therapy) phase I trial, in patients with advanced solid tumors, will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3 – 7, 2022 in Chicago, Illinois.